New antibody AK1967 tested in healthy men as potential shock therapy
Knowledge-focused
Completed
This Phase 1 study tested the safety and tolerability of a single intravenous dose of AK1967 (Procizumab) in 24 healthy male volunteers. AK1967 is an antibody that blocks a protein called DPP3, which may worsen blood pressure drops during cardiogenic shock. The study only looked …
Phase: PHASE1 • Sponsor: 4TEEN4 Pharmaceuticals GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC